Overview

3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer

Status:
Completed

Trial end date:
2008-02-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving 3-AP together with gemcitabine as second-line therapy works in treating patients with recurrent stage III or stage IV non-small cell lung cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Cancer Therapeutics Research Group

Collaborator:

National Cancer Institute (NCI)

Treatments:

Gemcitabine